Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 COV2 S COVID-19 vaccine - Janssen Pharmaceuticals

Drug Profile

Ad26 COV2 S COVID-19 vaccine - Janssen Pharmaceuticals

Alternative Names: 'Wuhan coronavirus vaccine - Janssen Pharmaceuticals; 2019-nCoV vaccine - Janssen Pharmaceuticals; Ad26 COVS1; Ad26-S.PP; Ad26.COV2 S; Ad26.COV2-S recombinant - Janssen Pharmaceuticals; Ad26.COV2.S; Coronavirus vaccine - Janssen Pharmaceuticals; Janssen COVID-19 Vaccine; JNJ-78436735; Single-dose COVID-19 vaccine - Janssen Pharmaceuticals; Single-Shot Janssen COVID-19 Vaccine; VAC 31518

Latest Information Update: 29 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceuticals
  • Class COVID-19 vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 22 Apr 2021 Janssen plans a phase II/III HORIZON 2 trial in COVID-2019 infections (Prevention, In adolescent, In adults, In children, In infants, In neonates) in Argentina, Australia, Brazil, Canada, Colombia, Finland, Italy, Mexico, Poland, South Africa, Spain, Sweden, Turkey, in UK and in USA, (IM) (EudraCT2020-005720-11)
  • 21 Apr 2021 Updated efficacy data from the phase III ENSEMBLE trial for COVID-2019 infections released by Johnson & Johnson
  • 20 Apr 2021 the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) provides updated guidance and labelling instructions for use of Ad26 COV2 S COVID-19 vaccine and its overall benefit-risk profile
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top